Blog

Compass Pathways Lost Its Co-Founders – Now What?

Apr 2 • 4 min read

In an unexpected turn of events, Compass Pathways plc (Nasdaq: CMPS), a leading figure in the mental health sector, witnessed a notable dip in its stock price, plunging over 12% following the announcement of its co-founders, George Goldsmith and Ekaterina Malievskaia, stepping down from the board. This significant development unfolds as the company advances through…

Buftoad: A Meme Coin for Psychedelics

Apr 2 • 3 min read

In a world where meme coins often surface with the promise of quick riches but little substance, Buftoad emerges as a beacon of purpose and potential. Launched on the vibrant Solana blockchain, this innovative meme coin quickly turned heads, not just for its financial allure but for its noble mission. At its heart, Buftoad aims…

PsyCan Welcomes Expansion of Insurance Coverage for Psychedelic-Assisted Therapy in Alberta

Apr 2 • 2 min read

OTTAWA, April 02, 2024 (GLOBE NEWSWIRE) — PsyCan, the not-for-profit trade association for the legal Canadian psychedelic medicine industry, welcomes the expansion of insurance coverage for psychedelic-assisted therapy (PaT) led by the Alberta Blue Cross. “We welcome Alberta Blue Cross as the first major provincial insurer to cover Psychedelic-Assisted Therapy in all of its forms,” said…

Compass Pathways To Participate in Upcoming 23rd Annual Needham Virtual Healthcare Conference

Apr 2 • 2 min read

LONDON, April 01, 2024 (GLOBE NEWSWIRE) — Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the 23rd Annual Needham Virtual Healthcare Conference at 8:00am ET on April 9, 2024. A live audio webcast of the presentation will be…

Algernon Pharmaceuticals to Move Forward with Psychedelic Drug DMT Stroke Research Program as its Lead Asset

Apr 1 • 3 min read

VANCOUVER, British Columbia, April 01, 2024 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it plans to move forward with its intravenous formulation of its AP-188 (“N,N-Dimethyltryptamine” or “DMT”) stroke research program as its lead asset, after having…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538